$56.18
1.041.89%
Last update: Nov 10, 4:21 PM
Cytokinetics Inc
CYTKNASDAQ
Cytokinetics fell 11.4% from $62.20 to $55.14, behind the S&P 500's +10.0%. Its worst day was Nov 5 (−12.7%), and its low came Nov 6 at $53.69.
Nov 10, 2025 – Nov 9, 2026 · picked from earnings, analyst actions, headlines and the biggest daily moves
EPS of $-1.50 missed the $-1.41 estimate on $17.8M revenue (est. $6.4M).
−10.3% · S&P 500 +0.8%
EPS of $-1.67 missed the $-1.65 estimate on $19.4M revenue (est. $8.5M).
Story events cover the past 12 months · Times ET
−2.9% · S&P 500 +1.4%
Cytokinetics closed at its highest level of the year, 40.3% above where the year started.
+6.2% · S&P 500 +1.6%
EPS of $-1.50 beat the $-1.62 estimate on $28.6M revenue (est. $17.2M).
−5.7% · S&P 500 +0.6%
Cytokinetics shares fell 7.5%, while the S&P 500 fell 0.2%.
−7.5% · S&P 500 −0.2%
EPS of $-1.37 beat the $-1.42 estimate on $47.6M revenue (est. $42.3M).
−12.7%, the year's worst day · S&P 500 −4.4%
Where it ended: a close of $55.14 on Nov 9, 2026. Up next: Q4 2026 earnings on Feb 23, 2027 (EPS est. $-1.38, revenue est. $65.9M).
Nothing in the past 12 months.
All CYTK dividend historyReplay the year: the line draws itself and stops at each of the 6 moments with what happened and how the stock reacted.
Chart by ChartIQ. Events, ratings, quote and fundamentals from Benzinga APIs. Daily bars for CYTK and SPY from Benzinga historical bars. Not investment advice.
